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The reported IgG seroprevalence against hepatitis E 
virus (HEV) in German blood donations is 6.8%, and 
HEV RNA detected in 0.08%, but documented evidence 
for HEV transmission is lacking. We identified two 
donations from a single donor containing 120 IU HEV 
RNA/mL plasma and 490 IU/mL. An infectious dose of 
7,056 IU HEV RNA was transmitted via apheresis plate-
lets to an immunosuppressed patient who developed 
chronic HEV. Further, transmission was probable in an 
immunocompetent child.
Hepatitis E virus (HEV) infection was diagnosed in 
December 2013 in Germany. Retrospective analysis 
identified the event as the first transfusion-associated 
hepatitis E virus (HEV) infection in the country. Here, 
we report baseline virological data on the case.
Case description
The patient (recipient 1), an immunocompromised man 
in his 40s, was positive for anti-HEV IgM and IgG using 
a recomLine HEV assay (Mikrogen, Munich, Germany), 
and HEV RNA was detected by real-time RT-PCR (Altona 
Diagnostics, Hamburg, Germany). Retrospective analy-
sis showed that he had been chronically infected with 
HEV since 24 July 2013, when HEV RNA was detected 
for the first time. When reviewing the medical charts 
it was noticed that the patient had received apheresis 
platelets from a single donor on 4 July 2013.
A lookback procedure was initiated and two viraemic 
donations of this donor were identified. The donor was 
a man in his 40s and asymptomatic around the time 
of the blood donations. He donated blood regularly 
every 14 days. The first viraemic donation (donation 1, 
day 0) was from 1 July 2013 and contained 120 IU HEV 
RNA/mL plasma, and the second donation (donation 
2, day 14) was from 15 July 2013 and contained 495 IU 
HEV RNA/mL plasma (Figure 1). This corresponds to an 
infectious dose of 7,056–8,892 IU HEV RNA in a total 
volume of 196–247 mL apheresis platelets transfused 
for donation 1 (assuming a residual plasma volume of 
0.33 mL per 1 mL apheresis platelets). For donation 2, 
an infectious dose of 30,888–37,273 IU HEV RNA was 
calculated. Real-time RT-PCR results were confirmed 
using a nested RT-PCR protocol [1]. All other donations 
(n=4) of this donor before and after donations 1 and 
2 tested negative by real-time RT-PCR and by nested 
RT-PCR (Figure 1).
The HEV nucleotide sequence of a 242 bp fragment of 
the ORF1 region was amplified and sequenced from 
donations 1 and 2 and from recipient 1 [1]. Phylogenetic 
analysis showed that the samples clustered together 
and were closely related to HEV genotype 3f, which is 
prevalent in Germany (Figure 2). The nearly complete 
nucleotide sequence (6,688 nt, GenBank accession 
number KJ873911) of the HEV isolate from recipient 
1 was determined and compared to sequences from 
Figure 1
Hepatitis E virus RNA concentration and serology results 
in an asymptomatic blood donor, Germany, 2013
HEV: hepatitis E virus; IU: international units.
Viral RNA concentration is given on the y-axis in IU/mL as 
indicated by diamonds. The thin broken line indicates the 
limit of detection of real-time RT-PCR (Altona Diagnostics). 
Symbol – denotes a negative result as measured by recomLine 
or recomWell assay, symbol + denotes a positive result, bd 
indicates borderline result.
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Figure 2
Rooted maximum likelihood phylogenetic consensus tree for ORF1 nucleotide sequences of selected hepatitis E virus 
isolates 
AT: Austria; CA: Canada; ch: chicken isolate; CN: China; CZ: Czech Republic; DE: Germany; ES: Spain; GR: Greece; gt: genotype; hu: human; IT: 
Italy; JP: Japan; KG: Kyrgyzstan; MM: Myanmar; MX: Mexico; NC: New Caledonia; NL: Netherlands; sw: swine; TD: Chad; US: United States.
The sequences of the presented cases (KJ547592 and KJ547593, bold) cluster in subgenotype 3f. The selected sequences represent the nearest 
homologues in GenBank and typical members of genotype 1, 2 and 4 [15]. An avian hepatitis E virus sequence was used as an outgroup. 
Numbers at the nodes indicate bootstrap values of greater than 50%. Sequences are denoted by GenBank identification number, country, 
International Organization for Standardization country code, source, and year of isolation (or publication). 
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donation 2 (4,251 nt, KJ873912). The nucleotide 
sequences were 100% identical proving transfusion-
associated transmission.
In donation 1 and 2, anti-HEV IgG and IgM were not 
detected using two different serological HEV assays 
(recomLine HEV and recomWell HEV, Mikrogen, Munich, 
Germany). Seroconversion of the donor was observed 
14 days after donation 2 (Figure 1). Levels of alanine 
aminotransferase, aspartate aminotransferase, biliru-
bin and gamma-glutamyl transferase were within nor-
mal range from days −28 to 42 relative to the first HEV 
RNA-positive donation. Detailed anamnestic explora-
tion of possible risk factors for HEV infection (e.g. occu-
pational exposure to pigs) remained inconclusive and 
the travel history was negative. 
Another four recipients were identified, who had 
received apheresis platelets from donations 1 or 2 
(Table). An immunocompetent child with a history of 
congenital heart disease tested positive for anti-HEV 
IgG and borderline for anti-HEV IgM (recomLine HEV 
and recomWell HEV) in a single sample eight months 
after receiving apheresis platelets from donation 
1. Real-time RT-PCR from this sample was negative 
(Table). Clinical symptoms suggestive of acute HEV 
infection were not reported. The available samples 
from the remaining recipients were all negative for HEV 
markers (Table). Two patients died for reasons other 
than HEV infection.
Discussion
HEV recently emerged as a transfusion-transmissi-
ble pathogen, with reports from France, the United 
Kingdom, and Japan [2-4]. In Europe, the vast majority 
of autochthonous HEV infections are caused by HEV 
genotype 3 (gt-3) and are linked to the consumption 
of contaminated food. In general, HEV gt-3 infection 
remains asymptomatic or presents as mild self-limited 
acute hepatitis [5]. HEV IgG seroprevalence in Europe 
ranges from 17% in Germany to 26% in France among 
the general population, indicating widespread contact 
with HEV [6,7]. A HEV IgG seroprevalence of 6.8% was 
determined among German blood donors in 2011, and 
HEV RNA was detected in 0.08% of donations [8,9]. 
Juhl et al. reported an HEV IgG incidence in donors of 
0.35% per year [9]. A total of 7.4 million blood products 
were administered in Germany in 2013, and between 
1,600 and 5,900 HEV RNA-positive blood donations 
could be occurring in Germany per year [8,10]. In the 
Netherlands, one HEV-positive donation per day was 
reported, which implies that transmission by transfu-
sion could be a likely event in both countries [11].
An estimated 30–40% of blood products in Germany 
were transfused to immunocompromised patients and 
these patients are at risk of developing chronic HEV 
gt-3 infection with increased mortality [5]. Sequence 
analysis of HEV strains from the Czech Republic, 
Germany and the Netherlands showed close homol-
ogy indicating a geographically confined circulation 
[8]. This is supported by the high degree of sequence 
identity of our and recent Czech and Dutch sequences. 
Zoonotic transmission from pigs to humans seems to 
be the major mode of infection, but occupational expo-
sure to pigs was not reported in our case [6].
Two important observations were made in this study. 
Firstly, we could show that the infectious dose required 
for HEV infection seems to be low, i.e. HEV RNA 
Table 
Characteristics and outcome of recipients of hepatitis E virus-positive donations, Germany, 2013 (n=5)
Transfusion recipients HEV status
Transfused 
infectious 
dose HEV RNA
Recipient, sex  
and age
Immuno-
compromised Outcome
HEV status 
determined, 
time after 
transfusion
HEV PCR Anti-HEV IgG status
Blood products from donation 1 
Apheresis platelets  
(196 mL) 7,056 IU #1, male 47 years Yes
Chronic HEV 
infection 6 months Positive Positive
Apheresis platelets  
(247 mL) 8,892 IU #2, male 6 years No
Probable HEV 
infection 8 months Negative Positive
Apheresis platelets  
(243 mL) 8,748 IU #3, female 70 years Yes Died, sepsis NA NA NA
Blood products from donation 2
Apheresis platelets 
(208 mL) 30,888 IU #4, male 71 years Yes
No HEV 
infection 5 months Negative Negative
Apheresis platelets  
(251 mL) 37,273 IU #5, male 71 years No
Died, 
arrhythmia NA NA NA
Apheresis platelets 
(249 mL) 36,976 IU #5, male 71 years No
Died, 
arrhythmia NA NA NA
HEV: hepatitis E virus; NA= Not applicable.
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concentrations close to the limit of detection of the 
real-time RT-PCR. Low levels of HEV RNA in asympto-
matic donors have already been reported but without 
evidence for transmission [8,9]. Interestingly, Juhl et 
al. speculated that viraemia of around 125 IU/mL in the 
presence of anti-HEV IgM was not sufficient for trans-
fusion-associated infection [9]. However, it is not clear 
if HEV antibodies can prevent infection. A recent study 
showed that infectious HEV could be propagated in cell 
culture in the presence of HEV-specific antibodies, sug-
gesting that they do not efficiently reduce virus infec-
tivity [12]. In addition, a clinical study demonstrated 
that anti-HEV IgG did not uniformly protect against re-
infection [13]. 
Secondly, the duration of viraemia in our asymptomatic 
donor did not exceed 45 days, based on the time inter-
val between the last and the first HEV RNA-negative 
donation. The interval of 14 days between first and last 
HEV RNA-positive donation was even shorter than the 
27 to 58 days reported by Slot et al., but could be due to 
the shorter sampling interval in our study [11]. From our 
and previously published data it is obvious that highly 
sensitive methods would be required if screening for 
HEV RNA were to be considered for blood products.
The second HEV transfusion-associated transmission 
possibly occurred in a child. However, we were not 
able to definitely prove transmission since only one 
sample was available. In light of the very low HEV sero-
prevalence among children in Germany it seems prob-
able that this child was infected by donation 1 [14]. It 
remains unclear why transfusion of donation 2 with a 
fourfold higher HEV RNA concentration did not result 
in infection, but this could be related to host factors.
To conclude, we could demonstrate that transmis-
sion of HEV by asymptomatic donors with low-level 
viraemia is possible. Current German guidelines in 
transfusion medicine do not recommend testing for 
HEV. Importantly, with regard to the possible severe 
consequences of transfusion-associated transmission 
of HEV, especially in immunocompromised patients, 
the necessity of screening for HEV RNA needs to be 
discussed in countries with a high HEV prevalence. 
However, more data regarding the HEV disease burden 
due to blood transfusions are needed before recom-
mendations can be made.
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